CEL-SCI Corporation to Present at the 8th Annual LD Micro Invitational

CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy biopharmaceutical company, today announced that it will be presenting at the 8th annual LD Micro Invitational on Tuesday, June 5 at 12:00 PM ET. Geert Kersten, Chief Executive Officer of CEL-SCI, will be giving the presentation and meeting with investors.

Mr. Kersten’s presentation will be webcast and available in the Investor Relations section of the Company's website at www.cel-sci.com/investor_relations.html. The webcast will be archived for 90 days following the presentation.

The conference will be held at the Luxe Sunset Bel Air Hotel in Los Angeles, California, will feature 230 companies in the small-cap / micro-cap space, and will be attended by over 1,000 individuals.

About LD Micro

LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. The firm hosts several influential conferences annually (Invitational, Summit, and Main Event).

About CEL-SCI Corporation

CEL-SCI is a Phase 3 cancer immunotherapy company. The Phase 3 study is fully enrolled with 928 patients. When it comes to cancer immunotherapy, CEL-SCI believes it is most logical to boost the patient’s immune system while it is still intact in order to have the greatest possible impact on survival. Therefore, CEL-SCI treats patients who are newly diagnosed with head and neck cancer with its lead investigational immunotherapy Multikine (Leukocyte Interleukin, Injection), BEFORE they have received surgery, radiation and/or chemotherapy. This approach is unique. Most other cancer immunotherapies are used only after conventional therapies have been tried and/or failed. Head and neck cancer represents about 6% of all cancers. Multikine has received Orphan Drug designation from the FDA for the treatment of head and neck cancer patients with advanced squamous cell carcinoma. CEL-SCI has received patents for Multikine from the US, Europe, China and Japan.

The Company’s LEAPS technology is being developed as a therapeutic vaccine for rheumatoid arthritis and is supported by grants from the National Institutes of Health. The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180522005303/en/

CEL-SCI CorporationGavin de Windt, 703-506-9460